Table 5.
Agents targeting other pathways under clinical investigation for the treatment of drug-resistant and metastatic colorectal cancer
|
Agent
|
Targeted molecule
|
Condition
|
Study phase
|
Clinical trial identifier
|
| CB-103 | Notch | Resistant to oxaliplatin or irinotecan-based therapy advanced or mCRC | Phase I/II | NCT03422679 |
| RO4929097 | Notch | mCRC | Phase II | NCT01116687 |
| WNT974 | Wnt | BRAF-mutant mCRC | Phase I/II | NCT02278133 |
| FOXY-5 | Wnt | mCRC | Phase I | NCT02020291 |
| LGK974 | Wnt | BRAF mutant CRC | Phase I | NCT01351103 |
| Vismodegib (GDC-0449) | Hedgehog | First-line therapy mCRC | Phase II | NCT00636610 |
| mCRC | Phase II | NCT00959647 | ||
| LDE225 | Hedgehog | mCRC | Phase I | NCT01576666 |
| NIS793 | TGF | Advanced CRC | Phase I | NCT02947165 |
| LY3200882 | TGF | Advanced chemotherapy -resistant CRC with an activated TGF-beta Signature | Phase I/II | NCT04031872 |
| Ganitumab | IGF-1R | KRAS wild-type mCRC | Phase I/II | NCT00788957 |
| KRAS-mutant mCRC | Phase II | NCT00813605 | ||
| Dalotuzumab (MK-0646) | IGF-1R | mCRC | Phase II | NCT00614393 |
| Cixutumumab (IMC-A12) | IGF-1R | mCRC resistant to EGFR therapy | Phase II | NCT00503685 |
Wnt: Wingless-related integration site; mCRC: Metastatic colorectal cancer; TGF: Transforming growth factor; IGF-1R: Insulin growth factor receptor-1; EGFR: Epidermal growth factor receptor.